Baxter International Aktie 911702 / US0718131099
29.53
USD
0.61
USD
2.09%
20.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Baxter International Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Baxter International Inc. | 3.00 | 1.16 | USD |
| 2022 | Baxter International Inc. | 2.26 | 1.15 | USD |
| 2021 | Baxter International Inc. | 1.26 | 1.09 | USD |
| 2020 | Baxter International Inc. | 1.19 | 0.96 | USD |
| 2019 | Baxter International Inc. | 1.02 | 0.85 | USD |
| 2018 | Baxter International Inc. | 1.11 | 0.73 | USD |
| 2017 | Baxter International Inc. | 0.94 | 0.61 | USD |
| 2016 | Baxter International Inc. | 1.14 | 0.51 | USD |
| 2015 | Baxter International Inc. | 3.33 | 1.27 | USD |
| 2014 | Baxter International Inc. | 2.80 | 2.05 | USD |
Gewinn je Aktie- Baxter International
| 5.2 23 | -4.8 22 | 2.5 21 | 2.1 20 | 1.9 19 | 3.0 18 | 1.3 17 |
Umsatz je Aktie- Baxter International
| 29.3 23 | 30.0 22 | 25.2 21 | 22.6 20 | 21.9 19 | 20.4 18 | 19.0 17 |
KGV- Baxter International
| 34.0 21 | 37.6 20 | 43.4 19 | 22.1 18 | 50.2 17 |
Baxter International Inc.: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 5.25 | -4.83 | 2.53 | 2.13 | 1.93 | 2.97 | 1.29 |
| Gewinn je Aktie unverwässert | -0.45 | -4.83 | 2.56 | 2.17 | 1.97 | 3.04 | 1.32 |
| Gewinn je Aktie verwässert | -0.45 | -4.83 | 2.53 | 2.13 | 1.93 | 2.97 | 1.29 |
| Dividende pro Aktie | 1.16 | 1.15 | 1.09 | 0.96 | 0.85 | 0.73 | 0.61 |
| Gesamtdividendenausschüttung in Mio. | 586.00 | 573.00 | 530.00 | 473.00 | 423.00 | 376.00 | 315.00 |
Baxter International Inc.: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 29.27 | 29.99 | 25.17 | 22.58 | 21.89 | 20.38 | 19.03 |
| KGV (Jahresendkurs, EPS unverwässert) | - | - | 33.96 | 37.64 | 43.36 | 22.13 | 50.17 |
| KGV (Jahresendkurs, EPS verwässert) | - | - | 33.96 | 37.64 | 43.36 | 22.13 | 50.17 |
| KGV (Jahresendkurs) | - | - | 33.96 | 37.64 | 43.36 | 22.13 | 50.17 |
| Dividendenrendite Jahresende in % | 3.00 | 2.26 | 1.26 | 1.19 | 1.02 | 1.11 | 0.94 |
| Eigenkapitalquote in % | 29.95 | 20.84 | 27.21 | 43.59 | 43.49 | 49.97 | 53.28 |
| Fremdkapitalquote in % | 70.05 | 79.16 | 72.79 | 56.41 | 56.51 | 50.03 | 46.72 |
Baxter International Inc.: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 14’813.00 | 15’113.00 | 12’784.00 | 11’673.00 | 11’362.00 | 11’127.00 | 10’561.00 |
| Umsatzveränderung in % | -1.99 | 18.22 | 9.52 | 2.74 | 2.11 | 5.36 | 3.92 |
| Bruttoergebnis vom Umsatz | 5’585.00 | 5’230.00 | 5’220.00 | 4’676.00 | 4’887.00 | 4’845.00 | 4’581.00 |
| Bruttoergebnisveränderung in % | 6.79 | 0.19 | 11.63 | -4.32 | 0.87 | 5.76 | 6.46 |
| Operatives Ergebnis | 1’600.00 | 1’304.00 | 2’083.00 | 1’818.00 | 1’908.00 | 1’776.00 | 1’484.00 |
| Veränderung Operatives Ergebnis in % | 22.70 | -37.40 | 14.58 | -4.72 | 7.43 | 19.68 | 29.16 |
| Ergebnis vor Steuern | -103.00 | -2’353.00 | 1’477.00 | 1’292.00 | 970.00 | 1’693.00 | 1’217.00 |
| Veränderung Ergebnis vor Steuern in % | 95.62 | - | 14.32 | 33.20 | -42.71 | 39.11 | -75.43 |
| Ergebnis nach Steuer | -76.00 | -2’433.00 | 1’284.00 | 1’102.00 | 1’001.00 | 1’630.00 | 724.00 |
| Veränderung Ergebnis nach Steuer in % | 96.88 | - | 16.52 | 10.09 | -38.59 | 125.14 | -85.42 |
Baxter International Inc.: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 19’808 | 22’392 | 24’400 | 11’293 | 10’281 | 7’825 | 7’995 |
| Langzeit Gesamtverbindlichk. pro Aktie | 26.21 | 34.98 | 40.20 | 15.77 | 13.93 | 9.73 | 9.56 |
| Eigenkapital | 8’468 | 5’895 | 9’121 | 8’726 | 7’912 | 7’816 | 9’116 |
| Veränderung Eigenkapital in % | 44.04 | -35.74 | 4.47 | 10.24 | 1.13 | -14.58 | 10.06 |
| Bilanzsumme | 28’276 | 28’287 | 33’521 | 20’019 | 18’193 | 15’641 | 17’111 |
| Veränderung Bilanzsumme in % | -0.04 | -15.61 | 67.45 | 10.04 | 16.32 | -8.59 | 10.07 |
Baxter International Inc.: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | -0.45 | -4.83 | 2.56 | 2.17 | 1.97 | 3.04 | 1.32 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 90.75 | -288.73 | 18.14 | 10.09 | -35.33 | 130.95 | -85.46 |
| Gewinn je Aktie (verwässert) | -0.45 | -4.83 | 2.53 | 2.13 | 1.93 | 2.97 | 1.29 |
| Veränderung Gewinn je Aktie (verwässert) in % | 90.75 | -290.99 | 18.58 | 10.51 | -35.16 | 130.88 | -85.65 |
| Anzahl Mitarbeiter | 60’000 | 60’000 | 60’000 | 50’000 | 50’000 | 50’000 | 47’000 |
| Veränderung Anzahl Mitarbeiter in % | 0.00 | 0.00 | 20.00 | 0.00 | 0.00 | 6.38 | -2.08 |
Baxter International Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Baxter International Inc. | Quartalszahlen | 30.01.2025 |
| Baxter International Inc. | Quartalszahlen | 24.04.2025 |
| Baxter International Inc. | Quartalszahlen | 24.07.2025 |
| Baxter International Inc. | Quartalszahlen | 23.10.2025 |
Baxter International Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 08.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 07.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 08.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 02.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Hauptversammlung | Annual General Meeting | 02.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 09.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 28.07.2022 |
| Hauptversammlung | Annual General Meeting | 03.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 17.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.21 |
| The Vanguard Group, Inc. | 11.35 |
| Vanguard Group, Inc. (Subfiler) | 11.35 |
| Dodge & Cox | 8.73 |
| Dodge & Cox | 8.73 |
| Pzena Investment Management LLC | 6.36 |
| Pzena Investment Management, Inc. | 6.31 |
| Dodge & Cox Stock Fund | 5.88 |
| State Street Corp. | 4.26 |
| BlackRock Fund Advisors | 3.43 |
| Vanguard Dividend Growth Fund | 3.25 |
| Vanguard Total Stock Market ETF | 3.16 |
| BlackRock Advisors LLC | 2.89 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2.76 |
| Vanguard 500 Index Fund | 2.65 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 47’000 | 50’000 | 50’000 | 50’000 | 60’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.22 | 0.22 | 0.23 | 0.23 | 0.21 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7’263 | 5’919 | 7’503 | 8’411 | 8’872 |
| Summe Anlagevermögen | 9’848 | 9’722 | 10’690 | 11’608 | 24’649 |
| Summe Aktiva | 17’111 | 15’641 | 18’193 | 20’019 | 33’521 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 7’995 | 7’825 | 10’281 | 11’293 | 24’400 |
| Summe Eigenkapital | 9’116 | 7’816 | 7’912 | 8’726 | 9’121 |
| Summe Passiva | 17’111 | 15’641 | 18’193 | 20’019 | 33’521 |
Adresse
| One Baxter Parkway, 60015-4625 Deerfield | |
| Telefon | +1 (224) 948-2000 |
| URL | http://www.baxter.com |
Management
|
Alok Sonig
Executive VP & President-Pharmaceuticals |
|
Amy A. McBride-Wendell
Independent Director |
|
Angela B. Lee
Chief Diversity Officer |
|
Caitlin Kelly
Manager-Finance Team |
|
Catherine R. Smith
Independent Director |
|
Cathy R Smith
Director |
|
Charles R. Patel
Chief Information Officer & Senior Vice President |
|
Christopher A. Toth
CEO-Renal Care & Acute Therapies businesses |
|
Clare Trachtman
Vice President-Investor Relations |
|
D. Brent Shafer
Lead Independent Director |
|
Darren Evans
Vice President-Global Technical Services |
|
David S. Rosenbloom
Executive Vice President & General Counsel |
|
David S. Wilkes
Independent Director |
|
Ellen K. Bradford
Secretary & Senior Vice President |
|
Gerard Greco
Chief Quality Officer & Senior Vice President |
|
Heather Knight
EVP, President-Medical Products & Therapies |
|
Heather Wechet
VP-Talent Management & Employee Relations |
|
James W. Borzi
Chief Supply Chain Officer & Executive VP |
|
Jeanne K. Mason
Chief Human Resources Officer & Executive VP |
|
Jeffrey A. Craig
Director |
|
Joel Todd Grade
Executive VP, Chief Financial & Accounting Officer |
|
José E. Almeida
Chairman, President & Chief Executive Officer |
|
Karen L. Leets
Treasurer & Senior Vice President |
|
Lynn Pawelski
Vice President-Global Regulatory Affairs |
|
Nancy M. Schlichting
Independent Director |
|
Nicolas Henry Roelofs
Development Manager |
|
Patricia B. Morrison
Independent Director |
|
Peter M. Wilver
Independent Director |
|
Reaz Rasul
EVP, President-Healthcare Systems & Technologies |
|
Stacey T. Eisen
Chief Communications & Corporate Marketing Officer |
|
Stephen H. Rusckowski
Independent Director |
|
Stephen Newman Oesterle
Independent Director |
|
Tobi Karchmer
SVP, Chief Medical & Scientific Officer |
|
William A. Ampofo
Independent Director |